Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982590 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982598 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL6898325 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1678967 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL176347 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982120 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982387 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21562191 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL8712178 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL12123492 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4719295-A | ANTIMICROBIAL, ANTIVIRAL, ANTILEUKEMIA | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | claimed |
| CN-121678872-A | Method for detecting iodo-nucleoside in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2026-03-17 | — | — | CN | disclosed |
| WO-2016168911-A1 | NUCLEOSIDE-BASED ANTI-BACTERIAL AND ANTI-PROTOZOAN DRUGS | UTI LIMITED PARTNERSHIP (CA) | 2016-10-27 | — | — | WO | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| EP-0604409-B1 | OLIGONUCLEOTIDE ANALOGS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1418179-A2 | Compositions and methods for detecting and modulating rna activity and gene expression | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-0604409-A4 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION. | ISIS PHARMACEUTICALS INC (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0604409-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| US-4719295-A | ANTIMICROBIAL, ANTIVIRAL, ANTILEUKEMIA | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
| US-4719295-A | ANTIMICROBIAL, ANTIVIRAL, ANTILEUKEMIA | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | PNP 94/4885LMNA 2680/4885TP53 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.